聚二二的口服生物可用性的性别特异性差异
Yi Kong1, Zhihai Chen1, Shuo Zhou1
1State Key Laboratory of Water Pollution and Green Resource Recycling, School of the Environment, Nanjing University, Nanjing 210023, People's Republic of China.
Environmental science & technology
|January 27, 2026
概括
雌性小鼠吸收更多的多二 (PCB) 由于提高脂质吸收和肠道微生物群的变化. 这种PCB生物可用性的性别差异影响了毒性途径,为有针对性的暴露减少策略提供了信息.
科学领域:
- 环境健康 环境健康
- 毒理学 毒理学 毒理学
- 毒理学中的性别差异
背景情况:
- 饮食摄入是多双 (PCB) 暴露的主要途径.
- 性别显著影响污染物吸收和不良影响,但PCB口服生物可用性的性别特异性差异不明.
研究的目的:
- 在成年小鼠中调查和阐明多双 (PCB) 口服生物可用性的性别特异性.
- 探索导致PCB吸收和代谢观察到的性别差异的潜在机制.
主要方法:
- 在不同暴露剂量的成年雌雄Balb/c小鼠中评估了PCB的口服生物可用性.
- 进行了便分泌分析,测量了食后血清apoB-48水平,并分析了肠道微生物群组成.
- 利用肝脏转录组学来比较PCB暴露后性别之间的基因表达变化.
主要成果:
- 与雄性 (12.3-18.8%) 相比,雌性小鼠的PCB口服生物利用率显著更高 (14.2-22.8%).
- 男人表现出较大的PCB便分泌,而女性具有更高的脂质同化效率和apoB-48水平,表明增强了基洛米克朗运输.
- 暴露于PCB改变了女性的脂质代谢基因,而男性在异生代谢和DNA毒性途径中表现出更强烈的反应. 肠道微生物群分析显示,女性的*Desulfovibrio*增加更为明显.
结论:
- 在PCB口服生物利用度的性别特异性是由脂质吸收,基洛米克朗运输和肠道微生物群组成的变化驱动的.
- 女性肠道屏障功能受损可能会导致PCB吸收的增强.
- 研究结果为基于性别的对PCB的毒理反应提供了关键的见解,有助于制定有针对性的风险减轻策略.
相关概念视频
Bioavailability Study Design: Absolute Versus Relative Bioavailability
329
Bioavailability is a crucial pharmacokinetic parameter that quantifies the proportion of an administered drug that reaches the systemic circulation and is available for therapeutic action. Regulatory agencies mandate the assessment of bioavailability, typically measured as the area under the drug plasma concentration-versus-time curve (AUC), to ensure the efficacy and safety of pharmaceutical products. These evaluations are categorized as absolute and relative bioavailability studies.Absolute...
329
Bioavailability: Overview
403
Bioavailability refers to the proportion of an administered drug that reaches the systemic circulation in its active, unaltered form. It is a crucial pharmacokinetic parameter that determines the effectiveness of a drug in achieving its intended therapeutic outcomes. The route of administration significantly influences bioavailability, with intravenous administration achieving 100% bioavailability as the drug directly enters the bloodstream. In contrast, oral administration often results in...
403
Bioavailability: Overview
4.4K
Bioavailability refers to the proportion of an unaltered drug that, after administration, enters the systemic circulation and can be distributed to the desired action site. Factors such as gastrointestinal (GI) absorption and liver biotransformation influence the bioavailability of a drug when it is administered orally. When a drug is administered intravenously, it enters the systemic circulation directly; by definition, its bioavailability is assumed to be 100%. The bioavailability of an...
4.4K
Sex-linked Disorders
108.6K
Like autosomes, sex chromosomes contain a variety of genes necessary for normal body function. When a mutation in one of these genes results in biological deficits, the disorder is considered sex-linked.
108.6K
Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems
205
Body:Bioavailability is a critical pharmacological concept that measures the extent and rate at which an active drug ingredient or therapeutic moiety enters the systemic circulation, remaining unchanged. It's a pivotal factor in determining a drug's efficacy and safety.The Biopharmaceutics Classification System (BCS) plays an essential role in drug development by categorizing drugs into four classes based on their solubility and permeability. This classification aids in understanding drug...
205
Bioavailability: Influencing Factors
365
Bioavailability refers to the extent and rate at which a drug reaches systemic circulation in its active form. Extent refers to the amount of the drug that makes it into circulation, while rate is the speed at which it enters circulation. It is influenced by several factors critical for optimizing drug formulations, dosing regimens, and therapeutic outcomes.Physicochemical properties of drugs and formulationsThe solubility, stability, and dissolution rate of a drug significantly impact its...
365


